Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients

J. Tonon; G. Koehne; N.H. Collins; M. Malloy; X. Chen; S. Bleau; M. Pessin; K. Smith; P. Maslak; S. Devlin; S.A. Giralt; R.J. O'Reilly; A.A. Jakubowski; R.C. Meagher

doi:10.1016/j.jcyt.2013.01.083

Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients

J. Tonon, G. Koehne, N.H. Collins, M. Malloy, X. Chen, S. Bleau, M. Pessin, K. Smith, P. Maslak, S. Devlin, S.A. Giralt, R.J. O'Reilly, A.A. Jakubowski, R.C. Meagher

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
DOIs	https://doi.org/10.1016/j.jcyt.2013.01.083
State	Published - Apr 1 2013
Event	Cytotherapy - Duration: Jan 4 2014 → …

Conference

Conference	Cytotherapy
Period	1/4/14 → …

Disciplines

Biology
Immunology and Infectious Disease

Access to Document

10.1016/j.jcyt.2013.01.083License: Unspecified

Cite this

Tonon, J., Koehne, G., Collins, N. H., Malloy, M., Chen, X., Bleau, S., Pessin, M., Smith, K., Maslak, P., Devlin, S., Giralt, S. A., O'Reilly, R. J., Jakubowski, A. A., & Meagher, R. C. (2013). Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients. Cytotherapy. https://doi.org/10.1016/j.jcyt.2013.01.083

Tonon, J, Koehne, G, Collins, NH, Malloy, M, Chen, X, Bleau, S, Pessin, M, Smith, K, Maslak, P, Devlin, S, Giralt, SA, O'Reilly, RJ, Jakubowski, AA & Meagher, RC 2013, 'Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients', Cytotherapy, 1/4/14. https://doi.org/10.1016/j.jcyt.2013.01.083

@conference{b6c4db64cf9742ae9b888f3b5ee00982,

title = "Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients",

author = "J. Tonon and G. Koehne and N.H. Collins and M. Malloy and X. Chen and S. Bleau and M. Pessin and K. Smith and P. Maslak and S. Devlin and S.A. Giralt and R.J. O'Reilly and A.A. Jakubowski and R.C. Meagher",

year = "2013",

month = apr,

day = "1",

doi = "10.1016/j.jcyt.2013.01.083",

language = "American English",

note = "Cytotherapy ; Conference date: 04-01-2014",

}

TY - CONF

T1 - Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients

AU - Tonon, J.

AU - Koehne, G.

AU - Collins, N.H.

AU - Malloy, M.

AU - Chen, X.

AU - Bleau, S.

AU - Pessin, M.

AU - Smith, K.

AU - Maslak, P.

AU - Devlin, S.

AU - Giralt, S.A.

AU - O'Reilly, R.J.

AU - Jakubowski, A.A.

AU - Meagher, R.C.

PY - 2013/4/1

Y1 - 2013/4/1

UR - http://www.sciencedirect.com/science/article/pii/S1465324913002181

U2 - 10.1016/j.jcyt.2013.01.083

DO - 10.1016/j.jcyt.2013.01.083

M3 - Presentation

T2 - Cytotherapy

Y2 - 4 January 2014

ER -

Final product composition after ex-vivo T-cell reduction: Miltenyi CliniMACS versus Baxter Isolex 300I in a large cohort of allogeneic trans-plant patients

Conference

Disciplines

Access to Document

Other files and links

Cite this